COMPARISON 1. ARIPIPRAZOLE vs OTHER ANTIPSYCHOTICS: Weight gain
COMPARISON 5. ARIPIPRAZOLE may leads to lower adverse effects: 6a. Metabolic‐ weight gain (7% or more of total… compared with OTHER ANTIPSYCHOTIC DRUGS (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
COMPARISON 5. ARIPIPRAZOLE vs OTHER ANTIPSYCHOTIC DRUGS Adverse effects: 6a. Metabolic‐ weight gain (7% or more of total body weight at 26 weeks ‐ medium‐term) · patients with schizophrenia COMPARISON 5. ARIPIPRAZOLE may leads to lower adverse effects: 6a. Metabolic‐ weight gain (7% or more of total… compared with OTHER ANTIPSYCHOTIC DRUGS (low certainty). Aripiprazole versus other atypical antipsychotics for schizophrenia (2013) · Cochrane Headline outcomes onlyearlier version CD006569.PUB4, superseded | RR 0.35 [0.19, 0.64] | 1 study · 330 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Aripiprazole versus other atypical antipsychotics for schizophrenia 2014 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.